The Hair Raising Rush for Ozempic's Successors The pharmaceutical industry is known for its ability to create and capitalize on trends.
Few have been as lucrative or swift as the rise of GLP 1 weight loss medications like Ozempic. Now, a new wave of companies is attempting to ride this wave into profitability.
Veradermics (MANE) and Absci (ABSI), both baldness drug stocks, are leading the charge. Their path to success is fraught with challenges.